HEAT BIOLOGICS INC (HTBX)

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.

Company Info

HEAT BIOLOGICS INC

627 Davis Drive, Suite 400

Morrisville NORTH CAROLINA 27560

P: 19192407133.0

CEO: Jeffrey Wolf

Employees: 49

Website: http://www.heatbio.com/